The role of fatty acids in the development and progression of nonalcoholic fatty liver disease
- PMID: 18430557
- PMCID: PMC2551556
- DOI: 10.1016/j.jnutbio.2007.10.001
The role of fatty acids in the development and progression of nonalcoholic fatty liver disease
Abstract
Nonalcoholic fatty liver disease (NAFLD) has emerged as a serious obesity-related disorder. NAFLD encompasses a wide spectrum of hepatic derangements ranging from a surfeit of fat in the liver (steatosis) to lipid surplus accompanied by fibrosis and cellular death (nonalcoholic steatohepatitis or NASH). The most widely accepted model to explain the progression from simple NAFLD to NASH is the "two-hit hypothesis," wherein fat over accumulation per se is not sufficient to induce the progression to statohepatitis, but renders the liver more susceptible to "second hits" that, once imposed upon the steatotic liver, cause further aberrations that culminate in the development of NASH. However, in light of recent data from our laboratory and elsewhere, we propose that an increased ratio of saturated-to-unsaturated fatty acids delivered to or stored within the liver may, in part, mediate the progression from simple steatosis to NASH. The molecular mechanisms that mediate the effect of saturated fatty acids are unclear, although proinflammatory cytokines, reactive oxygen species, and endoplasmic reticulum stress may all play a role. Collectively, these data suggest that saturated fatty acids may represent an intrinsic second hit to the liver that hastens the development of NASH.
Figures




Similar articles
-
Nonalcoholic Fatty Liver Disease and Staging of Hepatic Fibrosis.Adv Exp Med Biol. 2024;1460:539-574. doi: 10.1007/978-3-031-63657-8_18. Adv Exp Med Biol. 2024. PMID: 39287864 Review.
-
Nrf2 deletion causes "benign" simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet.Lipids Health Dis. 2013 Nov 4;12:165. doi: 10.1186/1476-511X-12-165. Lipids Health Dis. 2013. PMID: 24188280 Free PMC article.
-
Non-Alcoholic Fatty Liver Disease.Adv Exp Med Biol. 2017;960:443-467. doi: 10.1007/978-3-319-48382-5_19. Adv Exp Med Biol. 2017. PMID: 28585211 Review.
-
The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease.Toxicol Sci. 2014 Jan;137(1):26-35. doi: 10.1093/toxsci/kft230. Epub 2013 Oct 4. Toxicol Sci. 2014. PMID: 24097666 Free PMC article.
-
Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.Semin Liver Dis. 2008 Nov;28(4):407-26. doi: 10.1055/s-0028-1091985. Epub 2008 Oct 27. Semin Liver Dis. 2008. PMID: 18956297 Review.
Cited by
-
Quantitative proteomics analysis based on tandem mass tag labeling coupled with labeling coupled with liquid chromatography-tandem mass spectrometry discovers the effect of silibinin on non-alcoholic fatty liver disease in mice.Bioengineered. 2022 Mar;13(3):6750-6766. doi: 10.1080/21655979.2022.2045837. Bioengineered. 2022. PMID: 35246007 Free PMC article.
-
Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.Redox Biol. 2018 May;15:467-479. doi: 10.1016/j.redox.2018.01.009. Epub 2018 Feb 3. Redox Biol. 2018. PMID: 29413959 Free PMC article. Review.
-
Regulatory Non-coding RNAs Network in Non-alcoholic Fatty Liver Disease.Front Physiol. 2019 Mar 19;10:279. doi: 10.3389/fphys.2019.00279. eCollection 2019. Front Physiol. 2019. PMID: 30941061 Free PMC article. Review.
-
The adipokine/ceramide axis: key aspects of insulin sensitization.Biochimie. 2014 Jan;96:130-9. doi: 10.1016/j.biochi.2013.08.013. Epub 2013 Aug 20. Biochimie. 2014. PMID: 23969158 Free PMC article. Review.
-
High fat feeding induces hepatic fatty acid elongation in mice.PLoS One. 2009 Jun 26;4(6):e6066. doi: 10.1371/journal.pone.0006066. PLoS One. 2009. PMID: 19557132 Free PMC article.
References
-
- Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195–1200. - PubMed
-
- Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors. JAMA. 2003;289:76–79. - PubMed
-
- Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523–1529. - PubMed
-
- Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obesity Reviews. 2004;5:27–42. - PubMed
-
- Clark JM, Diehl A. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA. 2003;289:3000–3004. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources